Brief: Totality Of Evidence From Beat-Hf Study Shows Cvrx’S Barostim Provides Long-Term Benefits For Patients With Heart Failure
March 21 (Reuters) - CVRx Inc CVRX.O :
* TOTALITY OF EVIDENCE FROM BEAT-HF STUDY SHOWS CVRX’S
BAROSTIM
PROVIDES LONG-TERM BENEFITS FOR PATIENTS WITH HEART FAILURE
* CVRX INC - ANTICIPATES THAT REGULATORY SUBMISSION TO THE
FDA FOR
EXPANDED LABELING WILL BE MADE IN THE COMING MONTHS FOR BAROSTIM
* CVRX INC - WE LOOK FORWARD TO SUBMITTING BEAT-HF STUDY NEW
DATA
TO FDA TO PURSUE EXPANDED LABELING FOR BAROSTIM
Source text for Eikon: ID:
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CVRx
See all newsBrief: CVRx Announces Humana Medicare Advantage Coverage Policy For Barostim Therapy
CVRx's Q1 revenue rises 20%, beats expectations
Brief: CVRx Q1 Revenue USD 14.769 Million Vs. IBES Estimate USD 14.5 Million
CVRx preliminary Q1 revenue rises 20%, gross margin improves
CVRx Q4 revenue rises 4%, beats expectations